A Randomized, Double-Blind, Placebo-Controlled Study of Gelesis100: A Novel Nonsystemic Oral Hydrogel for Weight Loss
Frank L Greenway, Louis J Aronne, Anne Raben, Arne Astrup, Caroline M Apovian, James O Hill, Lee M Kaplan, Ken Fujioka, Erika Matejkova, Stepan Svacina, Livio Luzi, Lucio Gnessi, Santiago Navas-Carretero, J Alfredo Martinez, Christopher D Still, Alessandro Sannino, Cosimo Saponaro, Christian Demitri, Lorien E Urban, Harry Leider, Elaine Chiquette, Eyal S Ron, Yishai Zohar, Hassan M Heshmati, Frank L Greenway, Louis J Aronne, Anne Raben, Arne Astrup, Caroline M Apovian, James O Hill, Lee M Kaplan, Ken Fujioka, Erika Matejkova, Stepan Svacina, Livio Luzi, Lucio Gnessi, Santiago Navas-Carretero, J Alfredo Martinez, Christopher D Still, Alessandro Sannino, Cosimo Saponaro, Christian Demitri, Lorien E Urban, Harry Leider, Elaine Chiquette, Eyal S Ron, Yishai Zohar, Hassan M Heshmati
Abstract
Objective: This study aims to assess the efficacy and safety of Gelesis100, a novel, nonsystemic, superabsorbent hydrogel to treat overweight or obesity.
Methods: The Gelesis Loss Of Weight (GLOW) study was a 24-week, multicenter, randomized, double-blind, placebo-controlled study in patients with BMI ≥ 27 and ≤ 40 kg/m2 and fasting plasma glucose ≥ 90 and ≤ 145 mg/dL. The co-primary end points were placebo-adjusted weight loss (superiority and 3% margin super-superiority) and at least 35% of patients in the Gelesis100 group achieving ≥ 5% weight loss.
Results: Gelesis100 treatment caused greater weight loss over placebo (6.4% vs. 4.4%, P = 0.0007), achieving 2.1% superiority but not 3% super-superiority. Importantly, 59% of Gelesis100-treated patients achieved weight loss of ≥ 5%, and 27% achieved ≥ 10% versus 42% and 15% in the placebo group, respectively. Gelesis100-treated patients had twice the odds of achieving ≥ 5% and ≥ 10% weight loss versus placebo (adjusted OR: 2.0, P = 0.0008; OR: 2.1, P = 0.0107, respectively), with 5% responders having a mean weight loss of 10.2%. Patients with prediabetes or drug-naive type 2 diabetes had six times the odds of achieving ≥ 10% weight loss. Gelesis100 treatment had no apparent increased safety risks.
Conclusions: Gelesis100 is a promising new nonsystemic therapy for overweight and obesity with a highly desirable safety and tolerability profile.
Trial registration: ClinicalTrials.gov NCT03008954.
© 2018 The Authors. Obesity published by Wiley Periodicals, Inc. on behalf of The Obesity Society (TOS).
Figures
References
- Bessesen DH. Update on obesity. J Clin Endocrinol Metab 2008;93:2027‐2034.
- Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab 2004;89:2583‐2589.
- Pi‐Sunyer X. The medical risks of obesity. Postgrad Med 2009;121:21‐33.
- GBD 2015 Obesity Collaborators ; Afshin A, Forouzanfar MH, Reitsma MB, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med 2017;377:13‐27.
- Berrington de Gonzalez A, Hartge P, Cerhan JR, et al. Body‐mass index and mortality among 1.46 million white adults. N Engl J Med 2010;363:2211‐2219.
- Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014;384:766‐781.
- Xia Y, Kelton CM, Guo JJ, Bian B, Heaton PC. Treatment of obesity: pharmacotherapy trends in the United States from 1999 to 2010. Obesity (Silver Spring) 2015;23:1721‐1728.
- Prospective Studies Collaboration ; Whitlock G, Lewington S, Sherliker P, et al. Body‐mass index and cause‐specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 2009;373:1083‐1096.
- Samaranayake NR, Ong KL, Leung RY, Cheung BM. Management of obesity in the National Health and Nutrition Examination Survey (NHANES), 2007–2008. Ann Epidemiol 2012;22:349‐353.
- Thomas CE, Mauer EA, Shukla AP, Rathi S, Aronne LJ. Low adoption of weight loss medications: a comparison of prescribing patterns of antiobesity pharmacotherapies and SGLT2s. Obesity (Silver Spring) 2016;24:1955‐1961.
- Shannon K, Koo M, Leckenby N. Obesity disease coverage. Datamonitor Healthcare report 2017:56‐59.
- Booth HP, Prevost AT, Gulliford MC. Access to weight reduction interventions for overweight and obese patients in UK primary care: population‐based cohort study. BMJ Open 2015;5:e006642. doi:10.1136/bmjopen-2014-006642
- McLaughlin JC, Hamilton K, Kipping R. Epidemiology of adult overweight recording and management by UK GPs: a systematic review. Br J Gen Pract 2017;67:e676‐e683.
- Bray GA, Greenway FL. Pharmacological treatment of the overweight patient. Pharmacol Rev 2007;59:151‐184.
- Demitri C, Zohar Y, Heshmati HM, Urban LE, Aschenbach WG, Sannino A. Satiety and glycemic control enhancing properties vary between functional fibers, mixed salad, and a novel hydrogel (Gelesis100) [abstract 145‐LB]. Diabetes 2017;66(suppl 1A):LB38.
- US Food and Drug Administration . Is the product a medical device? . Updated March 22, 2018. Accessed July 17, 2018.
- Lim CT, Bershadsky A, Sheetz MP. Mechanobiology. J R Soc Interface 2010;7(suppl 3):S291‐S293.
- Astrup A, Kristensen M, Gnessi L, et al. Oral administration of Gelesis100, a novel hydrogel, significantly decreases body weight in overweight and obese subjects. Presented at: Endocrine Society’s 96th Annual Meeting and Expo; June 21‐24, 2014; Chicago, IL. Abstract SUN‐0897.
- Association American Diabetes . 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes‐2018. Diabetes Care 2018;41(suppl 1):S13‐S27.
- Guaraldi F, Pagotto U, Pasquali R. Predictors of weight loss and maintenance in patients treated with antiobesity drugs. Diabetes Metab Syndr Obes 2011;4:229‐243.
- Jensen MD, Ryan DH, Donato KA, et al. Guidelines (2013) for managing overweight and obesity in adults. Obesity (Silver Spring) 2014;22(S2):S1‐S410.
- Diabetes Prevention Program Research Group ; Knowler WC, Fowler SE, Hamman RF, et al. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009;374:1677‐1686.
Source: PubMed